首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1917784

青光眼治療市場－2026-2031年預測

Glaucoma Treatment Market - Forecast from 2026 to 2031

出版日期: 2026年01月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計青光眼治療市場將從 2025 年的 74.74 億美元成長到 2031 年的 99.41 億美元，複合年成長率為 4.87%。

受全球青光眼盛行率上升以及老年人口不斷成長（老年人患有老齡化相關眼科疾病的風險較高）的推動，青光眼治療市場正經歷顯著成長。各公司正致力於研發先進的眼藥水、聯合治療和新型藥物輸送系統，以提高治療效果和患者依從性。技術進步，特別是微創青光眼手術（MIGS）和緩釋植入，正在顯著改變青光眼的診斷和治療方法。

青光眼是一組以視神經損傷為特徵的疾病，通常與眼內壓升高有關，最終導致進行性性視力喪失。其主要亞型包括開放性青光眼青光眼和隅角閉鎖性青光眼，治療重點在於增加房水排放或抑制房水生成來降低眼內壓。在慢性疾病負擔日益加重、監管部門核准以及精準醫療投資的推動下，青光眼市場正經歷強勁成長。

青光眼盛行率不斷上升是推動市場成長的關鍵成長要素，而這又與年齡成長、家族病史、糖尿病、高血壓和眼部外傷等風險因素密切相關。老年人口的不斷成長也刺激了市場需求，因為與老齡化相關的生理變化會增加青光眼的風險，並且通常需要結合多種疾病進行全面治療。前列腺素類似物因其卓越的療效、每日一次給藥以及良好的副作用特徵，在藥物治療領域主導，從而提高了患者的依從性並促進了市場滲透。醫學影像技術、光同調斷層掃瞄（OCT）、選擇性雷射小梁小梁網整型術（SLT）以及疾病進展分析軟體的進步，正在提高診斷準確性和後續觀察能力。對高效處方眼藥水的需求，包括BETA阻斷劑、碳酸酐酶抑制劑、α促效劑、促效劑、前列腺素類似物及其複方製劑，反映了人們致力於在疾病早期階段進行有效管理並減輕醫療系統負擔的努力。

正在研發中的新型藥物和遞送機制為提高耐受性和維持療效提供了巨大的機會。

預計北美各地區將呈現顯著成長，這得益於先進的診斷基礎設施、簡化的治療模式、頻繁的監管核准以及強勁的藥物創新。

主要企業包括輝瑞公司、參天製藥株式會社、諾華公司、愛爾康公司和阿克倫營運公司。這些公司透過涵蓋藥物療法、外科器械和診斷整合的多元化產品組合，推動眼內壓調節、神經保護和微創介入治療方面未滿足的需求。

總體而言，人口結構變化、治療方法創新以及對早期療育的重視，使青光眼治療成為眼科進步的基石，並有望實現持續的市場成長。

本報告的主要優勢：

深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
市場促進因素與未來趨勢：探索市場促進因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用這些見解，在快速變化的環境中做出策略決策，並發現新的商機和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

以下是一些公司如何使用這份報告的範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

研究範圍：

2021年至2025年的歷史數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

The glaucoma treatment market is expanding significantly, driven by the rising global prevalence of glaucoma and the growing geriatric population susceptible to age-related ocular conditions. Companies are innovating with advanced eye drops, combination therapies, and novel drug delivery systems to improve efficacy and patient adherence. Technological progress is reshaping diagnosis and intervention, particularly through minimally invasive glaucoma surgery (MIGS) and sustained-release implants.

Glaucoma encompasses a group of disorders characterized by optic nerve damage, typically linked to elevated intraocular pressure, leading to progressive vision loss. Primary subtypes include open-angle and angle-closure glaucoma, with treatment focused on reducing intraocular pressure via enhanced aqueous humor drainage or reduced production. The market is growing robustly, supported by escalating chronic disease burden, regulatory approvals, and investments in precision therapies.

Key growth drivers include the increasing prevalence of glaucoma, influenced by risk factors such as advanced age, family history, diabetes, hypertension, and ocular trauma. The expanding geriatric demographic amplifies demand, as age-related physiological changes heighten susceptibility and often necessitate multifaceted management alongside comorbidities. Prostaglandin analogs dominate pharmacotherapy due to superior efficacy, once-daily dosing, and favorable side-effect profiles, promoting adherence and market penetration. Advancements in medical imaging, optical coherence tomography (OCT), selective laser trabeculoplasty (SLT), and progression analysis software are elevating diagnostic precision and monitoring capabilities. Demand for efficient prescription eye drops-encompassing beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cholinergics, prostaglandin analogs, and combinations-reflects efforts to control early-stage disease and alleviate healthcare system strain.

Pipeline therapies represent substantial opportunities, with ongoing developments in novel agents and delivery mechanisms aimed at enhanced tolerability and sustained action.

Geographically, North America is anticipated to exhibit significant growth, underpinned by advanced diagnostic infrastructure, streamlined treatment frameworks, frequent regulatory approvals, and robust pharmaceutical innovation.

Leading companies include Pfizer Inc., Santen Pharmaceutical Co., Ltd., Novartis AG, Alcon Inc., and Akron Operating Company LLC. These entities drive progress through diversified portfolios spanning pharmacologics, surgical devices, and diagnostic integrations, addressing unmet needs in pressure modulation, neuroprotection, and minimally invasive interventions.

Overall, the market is poised for sustained expansion, propelled by demographic shifts, therapeutic innovation, and emphasis on early intervention, positioning glaucoma management as a cornerstone of ophthalmic care advancement.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Glaucoma Treatment Market Segmentation

By Disease Type
Open Angle Glaucoma
Angle Closure Glaucoma
Others
By Drug Class
Prostaglandin Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLAUCOMA TREATMENT MARKET BY DISEASE TYPE

5.1. Introduction
5.2. Open Angle Glaucoma
5.3. Angle Closure Glaucoma
5.4. Others

6. GLAUCOMA TREATMENT MARKET BY DRUG CLASS

6.1. Introduction
6.2. Prostaglandin Analogs
6.3. Beta-blockers
6.4. Adrenergic Agonists
6.5. Carbonic Anhydrase Inhibitors
6.6. Others

7. GLAUCOMA TREATMENT MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Online Pharmacy

8. GLAUCOMA TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others